RUNX1 dosage in development and cancer

Lie-A-Ling, M., Mevel, R., Patel, R., Blyth, K. , Baena, E., Kouskoff, V. and Lacaud, G. (2020) RUNX1 dosage in development and cancer. Molecules and Cells, 43(2), pp. 126-138. (doi: 10.14348/molcells.2019.0301) (PMID:31991535) (PMCID:PMC7057845)

[img] Text
209950.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.


Publisher's URL:


The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Blyth, Professor Karen
Authors: Lie-A-Ling, M., Mevel, R., Patel, R., Blyth, K., Baena, E., Kouskoff, V., and Lacaud, G.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Molecules and Cells
Publisher:Korean Society for Molecular and Cellular Biology
ISSN (Online):0219-1032
Published Online:24 January 2020
Copyright Holders:Copyright © 2020 Korean Society for Molecular and Cellular Biology
First Published:First published in Molecules and Cells 43(2): 126-138
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record